Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics [4]

Lung Cancer

Volumn 51, Issue 1, 2006, Pages 137-138

  Zandwijk, Nico Van ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB;

CANCER SURVIVAL; CLINICAL TRIAL; ECONOMIC ASPECT; EUROPE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INSURANCE; LETTER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MORBIDITY; MORTALITY; PALLIATIVE THERAPY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL;

CARCINOMA, NON-SMALL-CELL LUNG; COST OF ILLNESS; FEES, PHARMACEUTICAL; HUMANS; LUNG NEOPLASMS; PATIENT COMPLIANCE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 30644470180     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.08.016     Document Type: Letter

References (4)

1. R. Loddenkemper G.J. Gibson Y. Sibille European white lung book 2003 ERSJ London
2. F.A. Shepherd, J.R. Pereiera, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
3. N.B. Leighl, W.S. Tsao, and D.L. Zawisza For richer, for poorer: a willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer Lung Cancer 2005
4. M. Taron, Ichiose, R. Rosell, and T. Mok Activating mutations in the tyrosisne kinase domain of the epidermal growth factor receptor are associated with improved survival in Gefitinib-treated chemorefractory lung adenocarcinomas Clin Cancer Res 11 2005 5878